AUTOSTAT II ANTI-CARDIOLIPIN IGG ELISA

K992440 · Cogent Diagnotics , Ltd. · MID · Sep 21, 1999 · Immunology

Device Facts

• Record ID: K992440
• Device Name: AUTOSTAT II ANTI-CARDIOLIPIN IGG ELISA
• Applicant: Cogent Diagnotics , Ltd.
• Product Code: MID · Immunology
• Decision Date: Sep 21, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5660
• Device Class: Class 2

Intended Use

Enzyme linked immunosorbent assay method for the semi-quantitative determination of specific IgG autoantibodies to cardiolipin in human serum. Uses: The results of the anti-cardiolipin assay can be used as an aid in the diagnosis of diseases associated with elevated levels of anti-cardiolipin antibodies including antiphospholipid syndrome. Levels of these autoantibodies are one indicator in a multi-factorial diagnostic regime. The assay may be used on the Hycor Hy•Tec Automated EIA instrument. For in vitro diagnostic use only.

Device Story

Autostat II Anti-Cardiolipin IgG ELISA is an in vitro diagnostic assay for detecting IgG autoantibodies to cardiolipin in human serum. Device utilizes enzyme-linked immunosorbent assay (ELISA) methodology; designed for use on Hycor Hy•Tec Automated EIA instrument. Operated by laboratory personnel in clinical settings. Input is human serum sample; output is semi-quantitative measurement of IgG autoantibodies. Results serve as one indicator within multi-factorial diagnostic regime for conditions like antiphospholipid syndrome. Healthcare providers use output to support clinical diagnosis of autoimmune-related conditions.

Clinical Evidence

No clinical data provided in the document; substantial equivalence is based on the 510(k) regulatory review process.

Technological Characteristics

Enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgG autoantibodies. Designed for use on the Hycor Hy•Tec Automated EIA instrument. In vitro diagnostic use only.

Indications for Use

Indicated for semi-quantitative determination of IgG autoantibodies to cardiolipin in human serum as an aid in diagnosing diseases associated with elevated anti-cardiolipin levels, such as antiphospholipid syndrome. For professional in vitro diagnostic use.

Regulatory Classification

Identification

A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).

Reference Devices

• Hycor Hy•Tec Automated EIA instrument

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES" in all caps. The text is in a bold, serif font. The text is centered on the image and takes up most of the space. The background is white.

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol resembling an abstract caduceus, with three wavy lines representing snakes intertwined around a staff.

SEP 2.1 1999

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Danielle M. Knight Ouality Manager Cogent Diagnostics Limited Pentlands Science Park Bush Loan, Penicuik Midlothian EH26 0PL Scotland, UK

Re: K992440

> Trade Name: Autostat™ II Anti-CARDIOLIPIN IgG ELISA Regulatory Class: II Product Code: MID Dated: July 16, 1999 Received: July 22, 1999

Dear Ms. Knight:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours.

Steven Sutman

Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Page 1 of 1

510(k) Number (if known): K992440

Device Name: Auto stat II

Anti-Candolipin IgG ELISA

Indications For Use:

Enzyme linked immunosorbent assay method for the semi-quantitative determination of specific IgG autoantibodies to cardiolipin in human serum.

Uses:

The results of the anti-cardiolipin assay can be used as an aid in the diagnosis of diseases associated with elevated levels of anti-cardiolipin antibodies including antiphospholipid syndrome.

Levels of these autoantibodies are one indicator in a multi-factorial diagnostic regime.

The assay may be used on the Hycor Hy•Tec Automated EIA instrument.

For in vitro diagnostic use only.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evalus

Quture. Makeri

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K992440

**Prescription Use**
(Per 21 CFR 801.109)

OR -

Over-The-Counter Use

(Optional Format 1-2-96)